CSIMarket
 


Nanoviricides inc   (NNVC)
Other Ticker:  
 
 

NNVC's Income from Cont. Operations Growth by Quarter and Year

Nanoviricides Inc 's Income from Cont. Operations results by quarter and year




NNVC Income from Cont. Operations (in millions $) FY 2024 FY 2023 FY 2022 FY 2021
IV Quarter June - -3.57 -1.78 -2.07
III Quarter March - -1.70 -1.79 -2.11
II Quarter December -2.11 -1.75 -1.92 -2.33
I Quarter September -1.97 -1.57 -2.61 -2.31
FY   -4.08 -8.59 -8.10 -8.82



NNVC Income from Cont. Operations second quarter 2024 Y/Y Growth Comment
Nanoviricides inc in the second quarter 2024 recorded loss from continued operations of $ -2.11 millions.

According to the results reported in the second quarter 2024, Nanoviricides Inc achieved the best Income from Cont. Operations growth in Major Pharmaceutical Preparations industry. While Nanoviricides Inc ' s Income from Cont. Operations no change of % ranks overall at the positon no. in the second quarter 2024.




NNVC Income from Cont. Operations ( Y/Y Growth %) 2024
2023 2022 2021
IV Quarter June - - - -
III Quarter March - - - -
II Quarter December - - - -
I Quarter September - - - -
FY   - - - -

Financial Statements
Nanoviricides Inc 's second quarter 2024 Income from Cont. Operations $ -2.11 millions NNVC's Income Statement
Nanoviricides Inc 's second quarter 2023 Income from Cont. Operations $ -1.75 millions Quarterly NNVC's Income Statement
New: More NNVC's historic Income from Cont. Operations Growth >>


NNVC Income from Cont. Operations (Quarter on Quarter Growth %)

2024
2023 2022 2021
IV Quarter June - - - -
III Quarter March - - - -
II Quarter December - - - -
I Quarter September - - - -
FY (Year on Year)   - - - -




Income from Cont. Operations second quarter 2024 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Income from Cont. Operations second quarter 2024 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Income from Cont. Operations by Quarter for the Fiscal Years 2021, 2022, 2023, 2024

Nanoviricides Inc 's Q/Q Income from Cont. Operations Growth


Income from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


NNVC's II. Quarter Q/Q Income from Cont. Operations Comment
Recent accomplishment of -2.11 millions by Nanoviricides inc appear even less good compare to the -1.97 millions loss from continued operations a quarter before.

Within Major Pharmaceutical Preparations industry Nanoviricides inc achieved highest sequential Income from Cont. Operations growth. While Nanoviricides Inc 's Income from Cont. Operations growth quarter on quarter, overall rank is .


Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


NNVC's II. Quarter Q/Q Income from Cont. Operations Comment
Recent accomplishment of -2.11 millions by Nanoviricides inc look even more unfavourable compare to the loss from continued operations -1.97 millions a quarter before.

Within Major Pharmaceutical Preparations industry Nanoviricides inc achieved highest sequential Income from Cont. Operations growth. While Nanoviricides Inc 's Income from Cont. Operations growth quarter on quarter, overall rank is .


Nanoviricides Inc 's 12 Months Income from Cont. Operations Growth Year on Year


Income from Cont. Operations TTM Growth

12 Months Ending
(Dec 31 2023)
12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
Cumulative Income from Cont. Operations 12 Months Ending $ -9.36 $ -8.99 $ -8.59 $ -6.80 $ -6.89
Y / Y Income from Cont. Operations Growth (TTM) - - - - -
Year on Year Income from Cont. Operations Growth Overall Ranking # # # # #
Seqeuential Income from Cont. Operations Change (TTM) - - - - -
Seq. Income from Cont. Operations Growth (TTM) Overall Ranking # # # # #




Cumulative Income from Cont. Operations growth Comment
Nanoviricides Inc ' has realized cumulative trailing twelve months loss from continued operations of $ -9 millions in the Dec 31 2023 period.
The situation is getting worse as the cumulative loss from continued operations is inflating from $ -8.99 millions for the period from Sep 30 2023 to Dec 31 2022 and $ -7.064437 millions for the twelve months ending in the quarter Dec 31 2022.

Nanoviricides inc achieved highest trailing twelve month year on year Income from Cont. Operations growth. While overall Income from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Income from Cont. Operations growth Comment
Nanoviricides Inc ' has realized cumulative trailing twelve months loss from continued operations of $ -9 millions in the Dec 31 2023 period.
The business is worsening as the cumulative loss from continued operations is getting bigger from $ -8.99 millions in TTM ending quarter Sep 30 2023 and $ -7.064437 millions for the twelve months ending in the quarter Dec 31 2022 Alexis P. Edwards told.

Nanoviricides inc achieved highest trailing twelve month year on year Income from Cont. Operations growth. While overall Income from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Income from Cont. Operations Growth
Major Pharmaceutical Preparations Industry Income from Cont. Operations Growth Trends and Statistics
Healthcare Sector Income from Cont. Operations Growth Statistics
Income from Cont. Operations Growth Trends for overall market
NNVC's Income from Cont. Operations Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Income from Cont. Operations Growth
Lowest Ranking Income from Cont. Operations Growth
Income from Cont. Operations Growth for NNVC's Competitors
Income from Cont. Operations Growth for Nanoviricides Inc 's Suppliers
Income from Cont. Operations Growth for NNVC's Customers

You may also want to know
NNVC's Annual Growth Rates NNVC's Profitability Ratios NNVC's Asset Turnover Ratio NNVC's Dividend Growth
NNVC's Roe NNVC's Valuation Ratios NNVC's Financial Strength Ratios NNVC's Dividend Payout Ratio
NNVC's Roa NNVC's Inventory Turnover Ratio NNVC's Growth Rates NNVC's Dividend Comparisons



Companies with similar Income from Cont. Operations no change for the quarter ending Dec 31 2023 within Healthcare SectorY/Y Change %Income from Cont. Operations for the quarter ending Dec 31 2023
National Research Corporation33.38%$ 33.384 millions
West Pharmaceutical Services Inc 33.01%$ 33.010 millions
Hologic Inc31.54%$ 31.537 millions
Semler Scientific Inc 31.25%$ 31.250 millions
Takeda Pharmaceutical Company Limited30.34%$ 30.344 millions
Orasure Technologies Inc28.99%$ 28.987 millions
Tenax Therapeutics Inc 26.55%$ 26.554 millions
Conmed Corporation24.40%$ 24.402 millions
The Pennant Group Inc 22.84%$ 22.837 millions
Inmode Ltd 22.54%$ 22.535 millions
Option Care Health Inc 20.30%$ 20.299 millions
Vertex Pharmaceuticals Inc18.31%$ 18.305 millions
Avenue Therapeutics Inc 17.75%$ 17.748 millions
Dariohealth Corp 17.42%$ 17.417 millions
Steris Plc14.29%$ 14.287 millions
Medpace Holdings Inc 14.02%$ 14.021 millions
Zoetis Inc 13.70%$ 13.696 millions
Eli Lilly And Company13.01%$ 13.005 millions
Idexx Laboratories Inc12.96%$ 12.958 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com